Method/ology of Phases of Biomarker Discovery

被引:2
|
作者
Navanandan, Nidhya [1 ]
Searns, Justin [2 ,3 ,4 ]
Ambroggio, Lilliam [1 ,2 ]
机构
[1] Childrens Hosp Colorado, Sect Emergency Med, Aurora, CO USA
[2] Childrens Hosp Colorado, Sect Hosp Med, Aurora, CO USA
[3] Childrens Hosp Colorado, Sect Infect Dis, Aurora, CO USA
[4] Univ Colorado, Dept Pediat, Aurora, CO USA
基金
美国国家卫生研究院;
关键词
ASTHMA;
D O I
10.1542/hpeds.2022-007012
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Biomarkers are commonly used in pediatric medicine to identify disease and guide clinical management for children. Biomarkers can be used to predict risk of disease, provide diagnostic clarification, and offer prognostic expectations. Specimens for biomarker testing might require noninvasive collection (eg, urine, exhaled breath) or invasive procedures (eg, blood, bronchoalveolar lavage) and testing might use various methodologies (eg, genomics, transcriptomics, proteomics, metabolomics). Specimen type and testing methodology depends on the disease of interest, ability to obtain sample, and availability of biomarker testing. To develop a new biomarker, researchers must first identify and validate the target, and then determine the test characteristics of the biomarker. Once it has undergone initial development and testing, a new biomarker is then tested in the clinical setting before being implemented into practice. An ideal biomarker is one that is feasible to obtain, readily quantifiable, and offers meaningful information that impacts care. Learning how to reliably interpret the performance and clinical application of a new biomarker is an important skillset for all pediatricians in the hospital setting. Here we provide a high-level overview of the process from biomarker discovery to application. In addition, we provide an example for the real-world application of biomarkers as an opportunity for clinicians to build on their ability to critically evaluate, interpret, and implement biomarkers in clinical practice.
引用
收藏
页码:e181 / e185
页数:5
相关论文
共 50 条
  • [31] Biomarker discovery in ovarian cancer
    Tung, Celestine S.
    Wong, Kwong-Kwok
    Mok, Samuel C.
    WOMENS HEALTH, 2008, 4 (01) : 27 - 40
  • [32] Glycoscience aids in biomarker discovery
    Hua, Serenus
    An, Hyun Joo
    BMB REPORTS, 2012, 45 (06) : 323 - 330
  • [33] Advances in Cardiovascular Biomarker Discovery
    Ghantous, Crystal M.
    Kamareddine, Layla
    Farhat, Rima
    Zouein, Fouad A.
    Mondello, Stefania
    Kobeissy, Firas
    Zeidan, Asad
    BIOMEDICINES, 2020, 8 (12) : 1 - 19
  • [34] The sweet side of biomarker discovery
    Bosques, Carlos J.
    Raguram, S.
    Sasisekharan, Ram
    NATURE BIOTECHNOLOGY, 2006, 24 (09) : 1100 - 1101
  • [35] The potentials of glycomics in biomarker discovery
    Kam R.K.T.
    Poon T.C.W.
    Clinical Proteomics, 2008, 4 (3-4) : 67 - 79
  • [36] Targeted Metabolomics for Biomarker Discovery
    Griffiths, William J.
    Koal, Therese
    Wang, Yuqin
    Kohl, Matthias
    Enot, David P.
    Deigner, Hans-Peter
    ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2010, 49 (32) : 5426 - 5445
  • [37] Metabolomics and Cardiovascular Biomarker Discovery
    Rhee, Eugene P.
    Gerszten, Robert E.
    BIOCHIMICA CLINICA, 2013, 37 (05) : 419 - 427
  • [38] Proteomics for cancer biomarker discovery
    Srinivas, PR
    Verma, M
    Zhao, YM
    Srivastava, S
    CLINICAL CHEMISTRY, 2002, 48 (08) : 1160 - 1169
  • [39] A revolutionary approach to biomarker discovery
    Petricoin, Emanuel F.
    Liotta, Lance A.
    SCIENTIST, 2006, 20 (11): : 32 - 39
  • [40] PPD Biomarker Discovery Sciences
    Schulman, Howard
    BIOMARKERS IN MEDICINE, 2008, 2 (06) : 549 - 554